Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

13.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.1K
Antibody Structure and Classes01:25

Antibody Structure and Classes

7.6K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
7.6K
Immunoprecipitation01:20

Immunoprecipitation

5.5K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inducible rAAV producer cell lines yield vectors equivalent to transient transfection: a physicochemical and biological comparison.

Scientific reports·2026
Same author

Effect of surfactants on agitation-induced submicron and subvisible particles of therapeutic proteins.

Journal of pharmaceutical sciences·2026
Same author

Polymerization-Induced Functional Switching of Engineered Polyhydroxyalkanoate Synthase Directs Block Copolymerization.

Journal of the American Chemical Society·2026
Same author

Manufacture of adeno-associated virus vectors by a novel human-derived cell line HAT and comprehensive evaluation of the vectors.

Molecular therapy. Advances·2026
Same author

A system of paired polyether epoxide hydrolases enables a mouldable enzyme for consecutive ring cyclization cascades.

Nature chemistry·2026
Same author

Forced degradation analysis of recombinant adeno-associated virus serotype 8 based on analytical anion exchange chromatography coupled to orthogonal characterization.

Journal of pharmaceutical sciences·2026

Related Experiment Video

Updated: Apr 25, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K

Liquid formulation for antibody drugs.

Susumu Uchiyama1

  • 1Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan.

Biochimica Et Biophysica Acta
|August 19, 2014
PubMed
Summary

This review details rational liquid antibody formulation development, focusing on aggregation mechanisms and stability. Understanding antibody physicochemical properties is crucial for efficient biopharmaceutical formulation.

Keywords:
AggregationAntibodyColloidal stabilityConformational stabilityFormulationVirial coefficient

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.6K

Related Experiment Videos

Last Updated: Apr 25, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.6K

Area of Science:

  • Biopharmaceutical development
  • Protein aggregation
  • Antibody formulation science

Background:

  • Biopharmaceuticals offer high efficacy with fewer adverse effects, driving their increased use.
  • Liquid formulations are gaining prominence for antibody drugs.
  • Understanding antibody aggregation is key to developing stable liquid formulations.

Approach:

  • This review focuses on rational liquid antibody formulation development.
  • It considers antibody aggregation mechanisms, colloidal stability, and conformational stability.
  • The assessment of physicochemical properties, such as the second virial coefficient, is highlighted.

Key Points:

  • Rational formulation development requires understanding antibody aggregation pathways.
  • Colloidal and conformational stabilities are critical parameters for antibody drug products.
  • Physicochemical properties, including the second virial coefficient, inform formulation strategies.

Conclusions:

  • Developing stable liquid antibody formulations relies on a deep understanding of aggregation mechanisms.
  • Assessment of physicochemical properties is essential for efficient and rational formulation design.
  • This work contributes to the field of antibody formulation and biopharmaceutical development.